Evidence map›Paper›PMID 34542221›Full record

Trial reportDiabetes, obesity & metabolism2022

The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.

Jonathan M Wilson, Yanzhu Lin, M Jane Luo, Gary Considine, Amy L Cox, Lenden M Bowsman, Deborah A Robins, Axel Haupt, Kevin L Duffin, Giacomo Ruotolo

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 6 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 6 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jonathan M WilsonEli Lilly and Company, Indianapolis, IN, USA.
Yanzhu LinEli Lilly and Company, Indianapolis, IN, USA.
M Jane LuoEli Lilly and Company, Indianapolis, IN, USA.
Gary ConsidineEli Lilly and Company, Indianapolis, IN, USA.
Amy L CoxEli Lilly and Company, Indianapolis, IN, USA.
Lenden M BowsmanEli Lilly and Company, Indianapolis, IN, USA.
Deborah A RobinsEli Lilly and Company, Indianapolis, IN, USA.ORCID 0000-0001-9694-7319
Axel HauptEli Lilly and Company, Indianapolis, IN, USA.ORCID 0000-0003-4502-0470
Kevin L DuffinEli Lilly and Company, Indianapolis, IN, USA.
Giacomo RuotoloEli Lilly and Company, Indianapolis, IN, USA.ORCID 0000-0001-5247-5444
Eli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes. In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline, 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors. At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide. Tirzepatide 15 mg also decreased ICAM-1 levels versus placebo and dulaglutide, and high-sensitivity C-reactive protein (hsCRP) levels versus baseline and placebo, but not dulaglutide. GlycA, interleukin 6, vascular cell adhesion molecule 1, and N-terminal-pro hormone B-type natriuretic peptide levels were not significantly changed in any group. YKL-40, hsCRP, and ICAM-1 levels rapidly decreased within 4 weeks of treatment with tirzepatide 10 and 15 mg, whereas the decrease in leptin levels was more gradual and did not plateau by 26 weeks. In this hypothesis-generating exploratory analysis, tirzepatide decreased several biomarkers that have been associated with cardiovascular risk.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2BiomarkersGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHeart Disease Risk FactorsHumansHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsRisk FactorsTirzepatideBiomarkersdulaglutideGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsTirzepatidecardiovascular diseaseGIPGLP-1incretin therapytype 2 diabetes

Identifiers

PMID34542221
PMCPMC9292792
OpenAlexW3201242536

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.